Upcoming Investor Presentations by Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), a company renowned for its cutting-edge developments in biotechnology, is gearing up for a series of important investor presentations. The management team will take part in these key events, providing insights into their advancements and future direction in the world of medicine.
Details of the Presentations
Scheduled sessions include the renowned Jefferies London Healthcare Conference, where Regeneron will present at 3:30 p.m. GMT (10:30 a.m. ET) on an upcoming Monday. Following this, the Wolfe Research Healthcare Conference will see the company speak at 9:20 a.m. ET on the same day.
On Tuesday, Regeneron will participate in the 8th Annual Evercore Healthcare Conference at 1:20 p.m. ET, providing additional updates. The schedule continues with the Citi 2025 Global Healthcare Conference on Wednesday at 10:30 a.m. ET, allowing investors to gain valuable knowledge about the company’s pipeline and strategy.
Live Streaming Access
For those interested in tuning into these pivotal presentations, sessions will be streamed live and can be accessed via the "Investors & Media" page on Regeneron's official website. Following the live events, replays and transcripts will be archived for at least 30 days, ensuring that interested parties can catch up on the discussions and insights shared during these forums.
About Regeneron Pharmaceuticals
Regeneron, trading under the NASDAQ ticker REGN, stands as a pillar of innovation in the biotechnology field. Founded and driven by a team of physician-scientists, the company's mission is to invent, develop, and commercialize transformative medicines for patients grappling with serious health issues.
With a robust pipeline comprising treatments for significant diseases—including those affecting the eyes, allergic reactions, cancer, and more—Regeneron is committed to addressing diverse health challenges. The company's research capabilities, particularly through their proprietary technologies, enable them to create fully human antibodies and exciting new treatments. These endeavors propel the organization towards achieving meaningful advancements in medical science.
Regeneron harnesses the power of the Regeneron Genetics Center, enabling them to utilize genetic data in the quest for innovative treatment options. This data-driven approach is central to their exploration of new therapeutic avenues, enhancing their potential to discover solutions with lasting impacts.
Connect with Regeneron
Stay informed about Regeneron Pharmaceuticals and their latest advancements by visiting their official website or engaging with them on various social media platforms such as LinkedIn, Instagram, Facebook, and X. Engaging with Regeneron on these platforms allows stakeholders to follow their journey and remain updated on future developments.
Contact Information
For further inquiries regarding investor relations, please reach out to Ryan Crowe at Regeneron Pharmaceuticals. Contact can be made via phone at 914.847.8790 or by emailing ryan.crowe@regeneron.com.
Frequently Asked Questions
What events is Regeneron participating in?
Regeneron will participate in several investor presentations at significant healthcare conferences.
Where can I access the presentations?
The presentations will be live-streamed and archived on Regeneron's "Investors & Media" webpage.
What does Regeneron focus on?
Regeneron focuses on developing transformative medicines for serious diseases across various medical fields.
How long will the presentation replays be available?
Replays and transcripts will be available for at least 30 days following each presentation.
Who is the contact person for investor inquiries?
Ryan Crowe is the contact for investor relations at Regeneron Pharmaceuticals.
